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Objectives: The introduction of new interventional procedures is less regulated than for other 
health technologies such as pharmaceuticals.  Decisions are often taken on evidence of efficacy 
and short-term safety from small-scale usually observational studies.  This reflects the particular 
challenges of evaluating interventional procedures – the extra facets of skill and training and the 
difficulty defining a ‗new‘ technology. Currently, there is no framework to evaluate new 
interventional procedures before they become available in clinical practice as opposed to new 
pharmaceuticals. This paper proposes a framework to guide the evaluation of a new 
interventional procedure.  
Proposed framework: A framework was developed consisting of a four-stage progressive 
evaluation for a new interventional procedure: Stage 1: Development; Stage 2: Efficacy and 
short-term safety; Stage 3: Effectiveness and cost-effectiveness; and Stage 4: Implementation. 
The framework also suggests the types of studies or data collection methods that can be used 
to satisfy each stage.  
Conclusions: This paper makes a first step on a framework for generating evidence on new 











A framework for the evaluation of new interventional procedures 
 
Introduction 
The introduction of new technologies into health care should reflect a judgement that benefits 
outweigh any harm. Those making such decisions should be guided by evidence that is both 
reliable and timely and thereby avoid erroneous decisions that put patients at unnecessary risk 
or delay the introduction of helpful treatments. Interventional procedures are health technologies 
that can be used ―for diagnosis or treatment involving an incision, puncture, entry into a body 
cavity or the use of electromagnetic radiation.‖[1] Many interventional procedures also involve 
the use of medical devices. A medical device is defined as ‗any instrument, apparatus, 
appliance, software, material or other article, whether used alone or in combination, together 
with any accessories, including the software intended by its manufacturer to be used specifically 
for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by 
the manufacturer to be used for human beings for the purpose of diagnosis, prevention, 
monitoring, treatment or alleviation of disease..‘[2] Compared with other types of health 
technology, new interventional procedures including medical devices are subject to relatively 
little regulation, often entering clinical practice without a thorough assessment of safety and 
efficacy.[3-5] This contrasts with pharmaceuticals, which are subjected to rigorous assessment 
before they are routinely used in patients.[6-8];  
 
In the United Kingdom, the evaluation of pharmaceuticals follows a framework made up of four 
distinct progressive phases[9] (Box 1). 
Currently, there is no formal framework for the evaluation of interventional procedures and the 
framework used for the evaluation of medical devices is suboptimal[5]. The lack of a defined set 
of steps for the approval of interventional procedures may lead to patients being offered 
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treatments without access to adequate information on the nature and likelihood of benefits and 
harms and clinicians being uncertain which new treatments they should adopt. Furthermore, 
health systems have difficulty in managing the risks associated with new procedures and 
hospitals do not want to be taken by surprise by unexpected consequences arising from 
treatments.[3,10] Typically, the evaluation of interventional procedures stops at studies 
assessing safety and efficacy in small groups of patients.[11] For example, in the late 1980‘s 
optic nerve decompression surgery for nonarteritic anterior ischaemic optic neuropathy, a 
condition that is associated with a sudden and painless loss of vision, was performed very 
frequently with supporting data coming from small short-term case-series.[11] Years later, 
findings from a pragmatic[12] randomised controlled trial (RCT) indicated that this surgical 
treatment is both ineffective and potentially harmful as patients receiving surgery had a 
significantly greater risk of losing visual acuity.[11] Based on these findings the investigators 
recommended that its use should be abandoned.[11] Another example where early data was 
misleading is electronic fetal heart rate monitoring during labour.  This procedure was used for 
two decades based on evidence from case-series and comparative studies using historical or 
non-randomised concurrent controls. When results from RCTs became available, these 
showed no evidence of benefit to the fetus and that electronic fetal heart rate monitoring was 
potentially harmful to the mother by increasing the caesarean section rate two to three fold.[13] 
Box 2 shows examples of other interventional health technologies that were widely used in 
routine clinical practice before they were found to be ineffective or harmful.[14] 
In this paper we therefore argue that the evaluation of interventional procedures including or not 
a medical device (from this point onwards we refer to this as ―interventional procedures‖) should 
also be regarded as a progressive process rather than a discrete event focusing on short-term 
data on efficacy and safey by proposing a framework for their evaluation, and this echoes 
5 
 
arguments of Ergina and colleagues[15] on the need for a framework for generating evidence 
on interventional procedures. 
Why is the regulation of interventional procedures different? 
Table 1 summarises the main differences between pharmaceuticals and interventional 
procedures. A key difference is that the safety and efficacy of pharmaceuticals is mainly 
dependent upon the effect on the body, whereas the performance of interventional procedures 
depends not only on the technology itself, but also on operator skill. All new interventional 
procedures are likely to be affected by a learning curve;[16] for example, in a large multicentre 
RCT comparing open surgery with laparoscopic surgery for the treatment of colorectal cancer, 
the outcomes for the laparoscopic arm were seen to improve over time as surgical skill 
improved.[17] There are very few evaluations that have clearly demonstrated what the learning 
curve is for a new intervention. The key issue is the speed at which learning occurs and the 
ability of practitioners to see sufficient cases and learn quickly. This therefore increases 
complexity in evaluating interventional procedures in comparison to pharmaceuticals. 
Another difference is related to the types of studies available. RCTs provide the most reliable 
evidence to determine the value of a health technology.[18] For a long time, evaluation of 
pharmaceuticals through RCTs has been a widely accepted method to inform their introduction 
into the market and into national health systems. However, for interventional procedures, 
particularly surgical interventions, only 3% to 9% of the published literature comprises studies 
using an RCT design,[19] with the majority of data coming from case-series. The history of 
RCTs of surgical interventions is tainted with major flaws in their design and conduct (e.g. 
difficulties in recruitment and randomisation, measurement of outcomes, and the 
standardisation of surgical procedures) and poor reporting. It has therefore proved difficult to 
obtain valid conclusions. There has been an improvement to this problem in recent years partly 
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due to initiatives like the CONSORT† statement in 1996 with guidelines for reporting which are 
regularly updated to reflect methodological developments in the design and conduct of 
RCTs,[20,21] advances in trial methodology, design, and the Medical Research Council 
framework for complex interventions.[22] The differences between pharmaceuticals and 
interventional procedures pose major challenges in the interpretation of formal technology 
assessments, particularly the greater consideration of observational data, despite increased 
levels of sophistication in the statistical methods employed to summarise the evidence.[23]  
An example of how much challenging the evaluation of interventional procedures can be, was 
well illustrated in a recent study by Tarricone and Drummond[24] where they analyse the 
challenges of evaluating a health technology for the treatment of aortic stenosis called 
transcatheter aortic valve implantation (TAVI). TAVI appears to be a promising health 
technology to manage patients with this condition, however, the data available is slim, patient 
selection is variable making up a very heterogeneous study population, and the level of 
expertise of practitioners have been proven to be an important determinant of outcomes for 
TAVI.[24] Another aspect are the wider implications regarding reorganisation of services as a 
TAVI procedure requires a multidisciplinary team and is logistically more challenging.[24] Also, 
the investment decision for TAVI, as for other devices, might be harder to reverse. TAVI has 
already been modified and there are two types of devices that are currently being marketed. 
This means that we cannot assume that devices have equal effectiveness.[24]  Moreover, 
buying an expensive technology to carry out a clinical study when there are so many factors that 
might pose problems is risky since after completion of the study, the hospital is ‗stuck‘ with the 
new technology if results are not favourable. All these aspects pose greater challenges in the 
evaluation of interventional procedures than the evaluation of pharmaceuticals.      
                                                             
†
 CONSORT: Consolidated Standards for Reporting Trials 
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Nevertheless, how challenging an evaluation of a new technology will be, regardless of it being 
a pharmaceutical or an interventional procedure, will ultimately depend upon the context and the 
scale of the change in practice that will be required.  A new medication that requires the addition 
of frequent monitoring may be more problematic than replacing one surgical technique with 
another. 
 
A framework for the evaluation of a new interventional procedure 
The framework is illustrated in Figure 1. It has four stages: ‗development‘, ‗efficacy and short-
term safety‘, ‗effectiveness and cost-effectiveness‘ and ‗implementation‘. Details of each of 
these stages are presented in the Figure and in the text below. 
 
Procedures at Stage 1 (‘development’) are those that have been recently developed, in which 
most of the available information comes from the ‗innovators‘ or device manufacturers, as well 
as occasional case reports.  
Procedures at Stage 2 (‘efficacy and short-term safety’) are represented by evidence based on 
surrogate measures of effect and short-term safety outcomes. Evidence is produced under 
tightly controlled conditions typically arising from case-series, and explanatory trials, where 
patients are highly selected and interventions delivered under ‗optimal‘ clinical conditions 
(sometimes an expert centre) with a single or a few skilled operators.[25] While information 
about safety and efficacy of new interventional procedures is important for decision-makers, it is 
unlikely that it will be sufficient, because there are wider considerations when deciding whether 
or not to introduce a new procedure. A study exploring perceptions of UK National Health 
Service decision-makers regarding national guidance on the safety and efficacy of new 
interventional procedures showed that additional information over and above safety and efficacy 
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would be useful to help decide whether or not the new technology should be offered to patients 
in routine care.[26]  
 
Procedures at Stage 3 (‘effectiveness and cost-effectiveness’) are characterised by evidence 
that is typically generated from pragmatic RCTs and longer-term data from registries. At this 
stage, it is expected that the information about effects should be based on patient relevant 
outcomes, such as serious morbidity and quality of life outcomes. Also, at this stage it is 
expected that information regarding the cost-effectiveness of the new procedure in comparison 
to the current standard of care is available. Evidence at this level is particularly relevant to 
national healthcare systems where treatments compete with each other within a limited budget. 
 
At Stage 4 (‘implementation’), the interventional procedure has already been judged to be safe 
and efficacious, with evidence that the procedure is effective and cost-effective. At this stage, 
regular monitoring might be performed through the conduct of surveys or cohort studies and the 
analysis of registry data, to ensure the quality and safety of widespread use of the procedure.  
 
Although this framework is suggesting that the evaluation of an interventional procedure should 
be made up of four discrete stages, the generation of evidence about them can be expected to 
overlap. Nevertheless, the balance between the different types of evidence does change 
progressively over time.  
 
When should we not use the four staged framework? 
In suggesting a framework for the evaluation of interventional procedures, we are not trying to 
imply that this should be used unquestioningly. There might be situations in which waiting for an 
interventional procedure to reach stage four of the framework may be inappropriate or unethical. 
An interventional procedure that has not been fully evaluated in the terms of this framework 
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could be offered in situations: (1) where the patient suffers from a rare condition with no 
treatment with proven effectiveness; (2) where all other available treatments have failed; and (3) 
arising within the operating room, in which the plan might have been to deliver one procedure, 
but in the event, given certain unexpected patient characteristics or response to treatment, a 
new procedure was undertaken. This implies therefore that there are occasions when common 
sense, taking into account the clinical context, determines whether a practitioner decides to offer 
a new interventional procedure. We would like to highlight that the options that we described 
above are rules of rescue. It is possible that there are other exceptions for the use of such 
framework and therefore more consideration is required.  
 
Discussion  
This proposed framework encourages a progressive approach of evidence generation for 
interventional procedures. The importance of a staged approach to the evaluation of other 
health technologies, such as pharmaceuticals, is well established. Here it is advocated that this 
should be extended to interventional procedures to include not only assessments of safety, 
efficacy and effectiveness but also consider economic implications. Below we discuss the 
implications for policy and challenges associated with the application of this framework.  
 
Implications for policy 
- Pre-market considerations 
Currently, interventional procedures may be widely adopted before reliable information about 
their likely effects and resource use becomes available. The regulatory arrangements for the 
introduction of interventional procedures are fragmented. As discussed above many 
interventional procedures also involve the use of a medical device and although there is an 
European Directive by which the biomedical industry must comply,[27] the process of approving 
medical devices in Europe is considered flawed, lacks information, lacks transparency and 
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patient safety may be put at risk.[28] The approval process of high risk (category III) medical 
devices in Europe now includes an assessment and analysis of clinical data to verify the clinical 
safety (absence of unacceptable clinical risks) and the performance (ability to achieve intended 
purpose) of the device when used as intended by the manufacturer.[28] Such clinical 
investigations do not, however, evaluate efficacy or effectiveness. The current approval process 
of medical devices in Europe implies that the benefit is estimated before clinical effectiveness is 
confirmed[29] and it dangerously assumes that the benefit for the rapid availability of the 
medical device outweighs the consequences. Putting our framework in this context, the 
evaluation mandated by European authorities halts at Stage 1, where safety is considered, but 
lacks any attempts to evaluate clinical benefit. So, an increased pre-market evaluation of high 
risk devices at least up to Stage 2 should be considered with post-market mandatory data 
collection to fulfill Stages 3 and 4.       
 
- Post-market and other policy considerations 
The European Directive[27] stipulates that manufacturers must implement a ―medical device 
monitoring system‘ to monitor their products once on the market, but how they do this is not 
mandated, so reporting is generally low.[30] Therefore, it takes even longer for the risks and 
benefits associated with the use of the medical device to surface.  Evaluating interventional 
procedures further into Stage 3 and 4, especially those that include a medical device, helps 
identifying whether any risks are associated with surgical skill, or the device itself.  
 
Considering the proposed framework and the current situation in the UK,[31] where the National 
Institute for Health and Clinical Excellence (NICE) has a programme that issues guidance on 
the safety and efficacy of interventional procedures, it appears that their evaluation typically 
consists of Stage 1 and Stage 2. For many procedures, evaluation may halt at Stage 1 as 
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relatively few procedures are considered by the NICE Interventional Procedures Programme 
and therefore may be introduced into practice on the basis of Stage 1 evaluation only.   
 
Although there is a body in the UK that evaluates interventional procedures, only occasionally 
do interventional procedures undergo formal assessment of effectiveness and cost-
effectiveness. Also, interventional procedures guidance is not mandatory and there is no direct 
mechanism to control diffusion, however, ‗negative findings‘ normally stop a procedure. It is the 
responsibility of each organisation to implement the guidance and therefore the success of this 
Programme is dependent on appropriate engagement from the NHS.[1] This means that 
patients may be receiving suboptimal care, clinicians may be unsure about which procedures to 
adopt and may lack appropriate training, and health systems struggle to manage any 
unexpected harm that new treatments may cause.[3] The problem relates to how a health 
service should react to judgments of safety and efficacy. In this sense, the NICE Interventional 
Procedures Programme is not helping to further structure the diffusion of the technology. We 
argue that formal use of the four-stage approach would help to address this. NICE has partially 
tackled this gap by launching a new programme called the Medical Technologies Evaluation 
Programme, aiming at promoting a faster uptake of new medical technologies in the NHS and to 
encourage collaborative research, in both industry and the NHS, to generate evidence on the 
clinical utility and/or healthcare system benefits of selected technologies.[32] For the small 
number of interventional procedures that NICE will consider, evaluation will go through Stages 1 
to 3. NICE will consider only select procedures and for these, given that the burden of evidence 
has been put on the manufacturer it might be expected that further good quality primary 
research will be conducted for these technologies.  Nevertheless, the impact on research of this 
recent change are unclear and it is likely that many eligible interventional procedures will not be 
formally considered. Furthermore, the development of methods for the early evaluation of 
interventional is required especially given the belief that interventional procedures are harder to 
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evaluate than new pharmaceutical intervention.[24]  The framework outlined in this paper can 
however help guide the stage of evaluation in which a particular health technology is in regard 
to the current available evidence. 
 
This framework can also be used for existing technologies. It can be used to identify where in 
the cycle of evidence generation a technology is and make recommendations about what further 
research is needed and about how the health service should treat the technology. It can also be 
used to further demonstrate the limitations of current practices. For example, to highlight that 
actions to adopt or reject a technology at a point in time were reasonable based upon the 
evidence available at the time.   
 
Challenges for the application of the framework  
There are some difficulties in applying this theoretical approach of progression in the evaluation 
of an interventional procedure. One is the fact that it is unusual for research to be strictly linear 
or compartmentalised. This is because (1) individual studies may have elements of more than 
one stage; (2) where more than one evaluation has been performed on a technology, the 
emphasis may vary between the demonstration of efficacy and effectiveness; and (3) the 
concepts of efficacy and effectiveness are not uniformly accepted and the terms are often used 
interchangeably. This causes confusion regarding what the results of studies actually mean in 
practice and a framework addressing this difference would be useful.  
Another difficulty associated with the use of a possible framework that can be used for the 
evaluation of an interventional procedure concerns the lack of a standard definition for when a 
procedure should be considered ―new‖. Due to the nature of interventional procedures, it can 
sometimes be difficult to judge whether an interventional procedure is a new or an established 
procedure. This is because some ‗new‘ procedures are adaptations of existing practice or used 
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to treat conditions other than that for which they were initially conceived.  Health technology 
innovation can be viewed in terms of a spectrum.[33] At one end of the spectrum are major 
innovations. These are mainly novel therapies that are in general only allowed to enter routine 
clinical practice after several clinical trials have been carried out to test the value of the 
treatment. At the other end of the spectrum, are those therapies that represent minor changes 
of existent therapies that are deemed ‗appropriate‘ for clinical practice. In between those two 
extremes are those new technologies characterised as ‗moderate‘ changes. These have 
undergone little or no evaluation, and are adopted in routine practice because they are believed 
to be adaptations or improvements of established procedures, therefore ‗not requiring‘ a strict 
evaluation of their safety and efficacy. It is therefore with this latter type of health technology 
innovation that most problems are likely to arise.  
 
One such concern is the potential to cause unintended harm to patients. For example, 
laparoscopic cholecystectomy is a treatment that involved the merging of two well-established 
technologies:[34] open cholecystectomy, performed for over 100 years, and laparoscopic 
surgery, which was originally developed to diagnose and treat conditions in gynaecology. It 
appeared later, after the technology was already being routinely offered to patients, that the 
combination of these two procedures was not as safe as had been assumed, with laparoscopic 
surgery increasing the risk of serious billiary injuries that were difficult and costly to treat.[33] 
The criteria for an interventional procedure to be considered as ‗new‘ have therefore been the 
subject of much debate[35] and there is no standard definition. In the UK, for example, the 
Scottish Government states that an interventional procedure should be considered as ‗new‘ if a 
doctor no longer in a training post is using it for the first time in his or her NHS clinical 
practice.[35] In Australia, the definition is more stringent, where a new interventional procedure 
is defined as ‘one either not previously carried out in the facility in question or not previously 
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carried out within that facility by the practitioner requesting privileges to do so ’.[36] Stirrat 
adopted a more flexible definition, and defined a new procedure as one that is innovative or 
significantly different from those currently practiced.[37]   
 
Conclusion  
A framework for the evaluation of interventional procedures should not be regarded as a barrier 
to innovation and should not lead to a lack of access of beneficial technologies to patients. 
Instead, the objective is to promote good practice guidelines regarding the evaluation and the 
introduction of new interventional procedures into routine care. Although health technologies in 
many cases are a driver for better health outcomes, they are also a major driver for increased 
healthcare expenditure. Therefore, their appropriate evaluation is warranted so that not only the 
best care is provided to patients, but also healthcare resources are used in the most efficient 
manner. Many new health technologies are costly and take years to develop. However, as soon 
as the technology is developed, its dissemination can be rapid due to the media and to, perhaps 
most importantly, the multinational nature of the biomedical industry. To control the speed of this 
dissemination, many countries, including the UK, regulate the introduction of new technologies 
into routine clinical practice. This regulation is aimed to control which technologies should be 
offered to patients, in terms of demonstrated safety and benefits, and help health policy-makers 
manage the risks and resources that new technologies might pose.  
 
The current regulatory arrangements for interventional procedures are fragmented making the 
introduction of this type of health technologies inconsistent and difficult to control. Due to the 
complex nature of most interventional procedures, it is not surprising that there is not a 
framework yet, as there is for pharmaceuticals. This paper aims to inform further discussion 
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